Business Wire

CRIANN boosts bandwidth in French research and education network with Adtran FSP 3000

5.11.2024 11:00:00 EET | Business Wire | Press release

Share

Adtran today announced that the Centre Régional Informatique et d’Applications Numériques de Normandie (CRIANN) is using its FSP 3000 optical transport technology and ALM fiber monitoring platform to boost the capacity and resilience of its research and education network, thanks to the financial support of the Normandy Region. By integrating Adtran’s solution, the Normandy-based supercomputing center and provider of high-performance digital infrastructure is ensuring faster and more reliable connectivity for the region’s scientific and academic institutions. Adtran’s Elite partner Axians also played a key role in the installation and continues to deliver maintenance and support.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241104047734/en/

Adtran’s technology is helping CRIANN drive high-speed, secure and ultra-reliable connectivity throughout its research and education network. (Photo: Business Wire)

“Our fiber network promotes innovation and the advancement of scientific knowledge. We support academic institutions in several ways, including by enabling data-intensive simulations and AI research for which high-speed, secure and ultra-reliable connectivity is fundamental,” said Alain Bidaud, CTO of CRIANN. “Harnessing Adtran’s optical transport technology, we’ve boosted capacity across our fiber infrastructure while also rendering our services more resilient. The FSP 3000 enables a seamless transition from our existing transport network. What’s more, its modular architecture radically simplifies the upgrade process so we can augment the solution to efficiently and sustainably meet future demand.”

This major upgrade to CRIANN’s research and education network increases bandwidth across all three of its sites. Featuring Adtran’s FSP 3000 OpenFabric™ 1200, the new solution integrates an open and flexible OTN fabric with DWDM transponder functions that deliver up to 400Gbit/s per wavelength and supports multiple OTN and Ethernet client services from 10Gbit/s to 400Gbit/s on a single card. This enables CRIANN to boost transport capacity and ensures the network can easily scale to meet both current and future demands.

CRIANN has also deployed Adtran’s ALM in-service fiber monitoring platform, which provides rapid, detailed alerts in the event of any fiber disruption. Combined with Adtran’s Mosaic Network Controller and Fiber Director, it offers a sophisticated real-time geographic information system that delivers pinpoint accuracy in locating fiber issues. By empowering CRIANN’s maintenance team with a precise understanding of its fiber infrastructure, the technology helps reduce truck rolls, improves network availability and minimizes operating costs.

“Built on our FSP 3000 platform, CRIANN’s upgraded fiber infrastructure is ideally suited to meet the growing demands of research and education networks for higher capacity and greater reliability,” commented Stuart Broome, GM of EMEA sales at Adtran. “Harnessing our OpenFabric™ 1200 switchponder, the new solution supports Ethernet and OTN services up to 400Gbit/s. This technology simplifies operations and maximizes the potential of CRIANN’s fiber assets. With its new, robust network, CRIANN is empowering Normandy’s academic community to take their research to whole new levels.”

“At Axians, we believe in forging connections that matter, not just with technology but also through relationships. Our partnership with CRIANN and Adtran is a testament to this philosophy. Together, we’re ensuring CRIANN’s research and education network can adapt, evolve and meet future challenges,” noted Bruno Durand, GM of Axians communication and cloud Caen. “This deployment is about providing top-tier opportunities for scientists, teachers and students. By merging technical expertise with our commitment to delivering excellence, we’re ensuring that the region stays at the cutting edge of research and innovation.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

Published by 
ADTRAN Holdings, Inc. 
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241104047734/en/

Contacts

For media
Gareth Spence
+44 1904 699 358
public.relations@adtran.com

For investors
Rhonda Lambert
+1 256 963 7450
investor.relations@adtran.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye